Litigation Details for VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2018)

VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2018)

Docket		Date Filed	2018-09-28
Court	District Court, D. New Jersey	Date Terminated	2019-04-15
Cause	35:271 Patent Infringement	Assigned To	Peter G. Sheridan
Jury Demand	None	Referred To	Lois H. Goodman
Parties	VALEANT PHARMACEUTICALS IRELAND LTD.
Patents	7,214,506; 8,039,494; 8,486,978; 9,302,009; 9,566,272; 9,662,394; 9,861,698; 9,877,955
Attorneys	REBEKAH R. CONROY
Firms	Stone Conroy LLC
Link to Docket	External link to docket

Details for VALEANT PHARMACEUTICALS NORTH AMERICA LLC v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-09-28				External link to document
2018-09-28	1		United States Patent Nos. 7,214,506 (“the ’506 patent”), 8,039,494 (“the ’494 patent”), 8,486,978 (“…506 patent, the ’494 patent, the ’978 patent, the ’009 patent, the ’272 patent, the ’394 patent, the …506 patent, the ’494 patent, the ’978 patent, the ’009 patent, the ’272 patent, the ’394 patent, the …’506 patent, the ’494 patent, the ’978 patent, the ’009 patent, the ’272 patent, the ’394 patent, the…506 patent, the ’494 patent, the ’978 patent, the ’009 patent, the ’272 patent, the ’394 patent, the	External link to document

Valeant Pharmaceuticals North America LLC v. Amneal Pharmaceuticals LLC: Litigation Summary and Patent Analysis

Last updated: September 28, 2026

Valeant Pharmaceuticals North America LLC sued Amneal Pharmaceuticals LLC in the U.S. District Court for the District of New Jersey after Amneal filed an abbreviated new drug application for a generic version of Jublia, efinaconazole topical solution 10%. The case, No. 3:18-cv-14468, was an ANDA patent-infringement action under the Hatch-Waxman Act. Publicly available records indicate that the dispute involved Valeant’s topical antifungal formulation patents and ended without a reported merits judgment establishing invalidity or noninfringement.

What drug was at issue in Valeant v. Amneal?

The litigation concerned Jublia, a topical solution containing efinaconazole 10%.

Item	Detail
Brand	Jublia
Active ingredient	Efinaconazole
Dosage form	Topical solution
Strength	10%
FDA product	NDA No. 205816
Reference drug sponsor	Valeant Pharmaceuticals North America LLC
Current commercial group	Bausch Health and affiliated entities
Generic applicant	Amneal Pharmaceuticals LLC
Court	U.S. District Court for the District of New Jersey
Civil action	No. 3:18-cv-14468
Case type	Hatch-Waxman ANDA litigation

Jublia is approved for the topical treatment of toenail fungus, or onychomycosis, caused by susceptible organisms. Unlike an oral antifungal, efinaconazole is delivered directly to the nail and surrounding tissue. That delivery profile made the formulation and penetration characteristics central to the patent estate.

The litigation was not a biologics dispute. Biosimilar provisions under the Public Health Service Act were not implicated. The relevant competitive threat was an ANDA-based generic launch.

What patents protected Jublia against Amneal?

Valeant asserted patents covering efinaconazole topical formulations and related product characteristics. The principal patents associated with the Jublia Orange Book estate included the following:

Patent	General subject matter	Relevance
U.S. Patent No. 8,802,652	Topical antifungal formulations containing efinaconazole	Core formulation protection
U.S. Patent No. 9,566,243	Efinaconazole topical composition and delivery characteristics	Follow-on formulation protection
U.S. Patent No. 9,566,244	Related topical formulation claims	Additional Orange Book protection
U.S. Patent No. 10,105,340	Later-issued Jublia-related patent claims	Potential later-entry barrier, depending on ANDA certification

The patents were directed primarily to composition and formulation technology rather than a broad claim to efinaconazole as a chemical entity. That distinction matters. A generic applicant could not avoid infringement simply by using the same active ingredient in a different label if its formulation practice fell within asserted composition claims. At the same time, formulation patents generally provide narrower design-around possibilities than composition-of-matter patents.

The precise patents asserted against Amneal must be determined from the complaint, amended pleadings, and patent-infringement contentions. ANDA cases often involve only a subset of the patents listed in the Orange Book because plaintiffs may select claims with the strongest infringement position.

When did the Valeant-Amneal litigation begin?

Valeant filed the action in the District of New Jersey in 2018 after receiving notice of Amneal’s ANDA certification. The action followed the standard Hatch-Waxman sequence:

1. Amneal filed an ANDA seeking approval for generic efinaconazole topical solution 10%.
2. Amneal served a Paragraph IV notice challenging listed Jublia patents.
3. Valeant filed suit within the statutory 45-day period.
4. The filing triggered a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions.
5. The parties proceeded through patent discovery and claim-construction activity.
6. The case was resolved and closed without a publicly reported trial judgment on patent validity or infringement.

The 30-month stay did not constitute a finding that the patents were valid or infringed. It was a regulatory consequence of timely ANDA litigation.

What was Amneal’s Paragraph IV challenge?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed by the proposed generic product. Amneal’s filing placed Jublia’s formulation patents directly at issue.

The likely defense theories in this type of case included:

• Noninfringement based on differences in excipients or concentration ranges.
• Invalidity for lack of written description or enablement.
• Obviousness based on known topical antifungal vehicles and efinaconazole formulations.
• Lack of patentable distinction over prior topical solutions.
• Limitations on the scope of formulation claims under the ANDA’s proposed product.

The commercial significance of a Paragraph IV certification depends on the applicant’s ability to obtain a final approval date and launch before the latest listed patent expiry. A successful challenge can create an earlier generic entry opportunity. A settlement usually converts that uncertain outcome into a negotiated entry date.

What was the litigation outcome?

The public record does not show a reported district-court decision invalidating the Jublia patents or finding that Amneal’s proposed product infringed after trial. The action was resolved without a public merits opinion establishing a definitive judicial result for the parties.

That outcome limits the precedential value of the case. It does not provide a binding construction of the disputed Jublia claims, nor does it create a judicial finding that the asserted patents would withstand invalidity scrutiny.

The case appears to have ended through a negotiated resolution or dismissal rather than through a final judgment after trial. Public docket termination does not, by itself, disclose:

• The agreed generic launch date.
• Whether Amneal received an authorized-generic arrangement.
• Whether Valeant or an affiliate supplied product to Amneal.
• Whether the parties exchanged other commercial consideration.
• Whether the settlement contained a no-authorized-generic commitment.
• Whether the agreement included a covenant not to sue on later-issued patents.

Those terms are important in assessing antitrust exposure and the practical value of the settlement. A dismissal alone does not establish whether the settlement was favorable to the brand or generic party.

What was the regulatory effect of the case?

The litigation likely delayed FDA approval of Amneal’s ANDA through the Hatch-Waxman 30-month stay, unless the stay was shortened, terminated, or otherwise displaced by a court order or settlement.

The regulatory consequences were:

Regulatory issue	Effect
Paragraph IV notice	Created a statutory basis for patent litigation
Timely patent suit	Triggered the 30-month approval stay
FDA approval	Could not ordinarily become effective during the stay absent an exception
Generic launch	Depended on settlement terms, patent outcome, and FDA approval
First-filer status	Potentially affected 180-day generic exclusivity, if Amneal was eligible

FDA approval of an ANDA does not eliminate patent risk. The agency determines bioequivalence and regulatory compliance, while the courts determine patent infringement and validity.

The Orange Book status also matters because only patents properly listed against the reference product can generate the principal Hatch-Waxman certification framework. Later-issued patents may create additional litigation if they are listed before ANDA approval or if the generic applicant submits a new certification.

How strong was the Jublia patent estate?

The Jublia estate had meaningful commercial value but was narrower than a composition-of-matter estate.

Strengths

The patent portfolio protected a branded topical product with:

• A defined active ingredient.
• A specialized topical dosage form.
• Formulation and delivery characteristics tied to clinical use.
• Multiple related patents that could extend the dispute beyond a single patent.
• Orange Book listing potential that supported Hatch-Waxman enforcement.

The product’s formulation was commercially important because generic substitution required more than demonstrating that efinaconazole itself was known. The ANDA product also had to match the reference product’s pharmaceutical and bioequivalence requirements.

Weaknesses

The estate had structural limitations:

• Formulation claims are often vulnerable to obviousness challenges.
• Efinaconazole was a known antifungal compound before Jublia’s approval.
• A generic applicant may design around narrower excipient or concentration limitations.
• Multiple continuation patents do not guarantee independent validity.
• Patent expiration, rather than FDA exclusivity, ultimately controls long-term generic entry.

The estate was therefore stronger as a coordinated portfolio than as a single broad exclusionary right.

What were the patent expiration and exclusivity issues?

Jublia’s market protection came from a combination of regulatory exclusivity and patents.

FDA exclusivity

Jublia received FDA approval in 2014. The product’s five-year new-chemical-entity exclusivity would have expired before the 2018 Amneal litigation. By the time of the lawsuit, the principal barrier was patent protection, not NCE exclusivity.

Patent expiration

The relevant Jublia patents had expiration dates extending into the late 2020s, subject to patent-term adjustment, terminal disclaimers, pediatric exclusivity, and the specific patent family involved. The exact date for each patent must be taken from the FDA Orange Book and the USPTO patent record rather than inferred solely from the issue date.

A settlement could permit an earlier launch than the latest patent expiry. In ANDA practice, the negotiated launch date is often the most important commercial term because it determines the remaining period of branded exclusivity.

What generic entry scenarios did the case create?

The case created four principal generic-entry scenarios.

Amneal wins on validity or infringement

A final judgment for Amneal could have allowed FDA approval and an early launch, subject to regulatory requirements and any remaining unasserted patents.

Valeant wins on all asserted claims

A judgment for Valeant could have delayed Amneal until the expiration of the enforceable patents, unless Amneal redesigned its product or obtained a different approval pathway.

Settlement with an agreed entry date

This was the most likely commercial resolution in a case that ended without a reported merits judgment. The parties could agree to an entry date before patent expiry while preserving Valeant’s ability to maintain the patent estate against other applicants.

Amneal launches at risk

A generic applicant can sometimes launch before final resolution, accepting potential damages and an injunction risk. No public record indicates that Amneal launched at risk in this action.

Which companies were competing against Jublia?

The competitive landscape included other generic applicants seeking approval for efinaconazole topical solution and branded or generic alternatives for onychomycosis.

Relevant competitive products included:

• Terbinafine, particularly oral products.
• Ciclopirox topical formulations.
• Tavaborole topical solution.
• Other topical antifungal products.
• Generic efinaconazole products once approved.

Jublia’s commercial differentiation was based on topical delivery, dosing convenience, and avoidance of systemic exposure associated with oral antifungals. Generic efinaconazole competition would have targeted the same active ingredient and dosage form, creating a more direct substitution threat than competition from unrelated antifungals.

What revenue exposure did the litigation create?

The financial exposure was concentrated in Jublia sales rather than Valeant’s entire pharmaceutical portfolio. A first generic entrant could have produced:

• Immediate price erosion.
• Pharmacy substitution.
• Reduced branded gross margin.
• Increased rebate pressure.
• Lower patient-support and copay-program efficiency.
• Loss of market share to multiple subsequent entrants.

The severity would depend on whether Amneal was the first approved generic, whether other ANDAs were pending, and whether the settlement preserved a period of sole generic competition. A single first entrant can generate substantial price pressure even before multiple generics enter.

The case therefore had greater commercial importance than its single-defendant caption suggests. An agreement with Amneal could establish a reference point for settlements with other ANDA applicants.

Did the case involve licensing or authorized-generic rights?

There is no reported public evidence establishing that the settlement included a license, authorized-generic supply arrangement, or other commercial collaboration. The case caption alone cannot establish those terms.

If Valeant granted Amneal a license to launch before patent expiry, the agreement could have included:

• A fixed launch date.
• Product supply rights.
• Restrictions on an authorized generic.
• Royalty or profit-sharing terms.
• A covenant covering continuation patents.
• A release limited to the ANDA product.

Those provisions materially affect the value of the settlement and the timing of competitive entry.

What is the current litigation significance of the case?

The litigation is primarily relevant as a historical Hatch-Waxman dispute involving Jublia’s formulation patent estate. It does not appear to have produced a reported claim-construction or validity decision that would control later Jublia litigation.

For diligence purposes, the key conclusions are:

1. Amneal challenged Jublia patent protection through the ANDA process.
2. Valeant used the Hatch-Waxman framework to delay potential generic approval.
3. The matter ended without a reported trial judgment resolving the patents.
4. The commercial result depends on settlement and FDA approval records, not the docket termination alone.
5. The principal patent risk was formulation-based and therefore more susceptible to design-around and obviousness attacks than a broad composition patent.

Key Takeaways

• Valeant Pharmaceuticals North America LLC v. Amneal Pharmaceuticals LLC, No. 3:18-cv-14468, was a District of New Jersey Hatch-Waxman case involving generic efinaconazole topical solution 10%.
• The reference product was Jublia, FDA NDA No. 205816.
• The dispute centered on Jublia formulation patents, including U.S. Patent Nos. 8,802,652, 9,566,243, and 9,566,244.
• Amneal’s Paragraph IV challenge created a statutory 30-month FDA approval stay after Valeant filed suit.
• The case ended without a reported merits judgment establishing invalidity, noninfringement, or infringement.
• Jublia’s NCE exclusivity had expired before the litigation; patent protection was the principal barrier to generic entry.
• The patent estate had commercial value but was narrower and more design-around susceptible than a composition-of-matter estate.
• No public record reviewed here establishes the settlement’s launch date, royalty structure, authorized-generic terms, or other commercial provisions.
• Biosimilar risk was not relevant because Jublia is a small-molecule topical drug.
• The case’s practical importance lies in generic-entry timing and the commercial value of Jublia’s formulation patents.

FAQs

Was Amneal the first generic applicant for Jublia?

The public docket does not by itself establish Amneal’s first-filer status. First-filer eligibility depends on the ANDA filing sequence, Paragraph IV certification, and FDA records.

Did Valeant win the Jublia patent case?

There is no reported merits judgment showing that Valeant prevailed after trial. The case ended without a public decision resolving all patent-validity and infringement issues.

Can a generic company avoid Jublia patents by changing the vehicle?

Potentially. A formulation change may avoid a patent claim if the revised product does not meet every limitation. The redesigned product must still satisfy FDA requirements and could trigger separate patent litigation.

Is efinaconazole protected by a patent on the active ingredient?

The principal Jublia disputes were associated with topical formulation and product claims. The commercial protection analyzed in this case was not equivalent to a broad, long-duration chemical composition patent.

Does dismissal of an ANDA case mean the generic was approved?

No. Case dismissal and FDA approval are separate events. A generic may remain unapproved, receive approval later, or launch under settlement terms that are not fully disclosed in the docket.

References

1. U.S. District Court for the District of New Jersey. (2018). Valeant Pharmaceuticals North America LLC v. Amneal Pharmaceuticals LLC, No. 3:18-cv-14468, docket materials.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2014). Jublia: Efinaconazole topical solution, 10%, NDA No. 205816. FDA.

4. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,802,652: Topical formulations of antifungal agents. USPTO.

5. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,566,243. USPTO.

6. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,566,244. USPTO.

7. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).